14:04:29 Europe / Stockholm

Svenska | English

Pliant Therapeutics, Inc.

Filter

År

Typ

Språk

Rensa

2024-06-13 22:05:00 Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors +1,79%

2024-06-12 22:05:00 Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) +4,16%

2024-06-06 14:00:00 Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™ -4,63%

2024-05-22 00:50:00 Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference -2,81%

2024-05-14 13:30:00 Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis +3,44%

2024-05-01 14:00:00 Pliant Therapeutics to Participate in Upcoming Investor Events +7,11%

2024-03-27 15:23:38 Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference +2,90%

2024-03-12 12:30:00 Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis +4,20%

2024-02-27 22:03:00 Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results +3,61%

2024-02-04 21:29:07 Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

2024-01-03 14:00:00 Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference +0,56%

2023-11-13 22:30:00 Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis -7,09%

2023-10-31 21:03:07 Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer +5,16%

2023-10-19 14:00:00 Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023 +2,44%

2023-10-16 22:05:00 Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer +0,98%

2023-09-25 22:05:00 Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis -2,86%

2023-08-30 14:00:00 Pliant Therapeutics to Participate in Upcoming Investor Conferences +0,72%

2023-08-28 22:05:00 Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023 +1,78%

2023-08-09 22:03:00 Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results +0,06%

2023-08-09 14:00:00 Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis +0,06%

2023-07-25 14:00:00 Pliant Therapeutics to Participate in Upcoming Investor Conferences -0,68%

2023-06-23 13:30:00 Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™ -2,07%

2023-05-24 14:00:00 Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference +0,70%

2023-05-10 14:05:00 Pliant Therapeutics to Participate in Upcoming Investor Events +2,31%

2023-05-09 22:02:00 Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results +1,86%

2023-04-30 20:10:28 Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

2023-04-12 14:01:00 Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference -3,68%

2023-03-27 14:01:00 Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference +2,85%

2023-03-13 13:01:00 Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis +0,79%

2023-03-09 22:05:00 Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results -9,01%

2023-03-08 22:01:00 Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors +1,78%

2023-03-01 14:01:00 Pliant Therapeutics to Participate in Upcoming Investor Events -1,35%

2023-02-07 14:01:00 Pliant Therapeutics to Participate in Upcoming Investor Events -1,01%

2023-02-02 14:02:00 Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors -1,31%

2023-01-27 22:03:00 Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares -3,83%

2023-01-25 14:01:00 Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer +5,19%

2023-01-25 03:19:09 Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering +5,19%

2023-01-23 22:01:00 Pliant Therapeutics Announces Proposed Public Offering of Common Stock +34,52%

2023-01-22 20:00:00 Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis

2023-01-03 14:00:00 Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference -1,71%

2022-11-15 14:00:00 Pliant Therapeutics to Participate in Upcoming Investor Conferences +5,86%

2022-11-08 22:02:00 Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results -1,62%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Pliant Therapeutics, Inc.

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden